ProlyteORS, the flagship brand of Cipla Health Limited, has welcomed the recent directive from the Food Safety and Standards Authority of India (FSSAI), which mandates the removal of the term “ORS” from food and beverage product names, labels, and trademarks unless they conform to the medically approved Oral Rehydration Solution (ORS) formulation as defined by the World Health Organisation (WHO).
For Cipla Health, this directive reflects a vital alignment between regulatory intent and the brand’s long-standing ethos. ProlyteORS is a WHO-approved formulation, scientifically designed to provide the precise balance of electrolytes, glucose, and sodium necessary for effective therapeutic rehydration. With integrity and transparency at the core of its labelling and product practices, Cipla Health proudly stands as the #AsliORS, reinforcing its commitment to empowering consumers with trusted and evidence-based health solutions.
Commenting on the development, Mr. Shivam Puri, MD & CEO at Cipla Health Limited, said:
“The recent FSSAI directive is a significant step towards protecting consumer trust and safeguarding public health by bringing greater transparency and the availability of safe, effective rehydration solutions. At Cipla Health, we have always placed consumer trust at the forefront. Our market leading brand ProlyteORS has always adhered to the highest standards of formulation integrity and #AsliORS is more than a promise—it's our unwavering commitment to transparency, quality, and efficacy for every consumer.”
In light of this ruling, Cipla Health urges consumers to look for accurate labelling and credible certifications when selecting oral rehydration solutions, ensuring safety, authenticity, and effectiveness in every purchase.
Also Read
